#Canada #Laval #Bausch Health #Salix Pharmaceuticals #GI Scholars

Introduction

Bausch Health Companies Inc. has announced the opening of the application period for the 2026 Salix Gastrointestinal Health Scholars Program. This initiative aims to support students who are managing the challenges of living with gastrointestinal (GI) diseases and are pursuing higher education. This year, the program will award scholarships of up to $10,000 to ten exceptional students.

Commitment to Education

Aimee Lenar, Executive Vice President of U.S. Pharma at Bausch Health, expressed pride in offering this scholarship for the seventh consecutive year. The program seeks to empower those facing health challenges, enabling them to achieve academic success despite their circumstances. According to Lenar, “Salix's commitment to support these patients and make a difference in the lives of all communities we serve remains a top priority.”

Scholarship Details

The Salix Gastrointestinal Health Scholars Program is designed for students attending or applying to two- or four-year colleges, universities, or advanced vocational or technical schools during the 2026-2027 academic year. There are three categories of awards available:
1. Undergraduate Scholar Awards: For students pursuing undergraduate degrees.
2. Graduate Scholar Awards: For students pursuing graduate degrees.
3. Working and/or Single Parents Scholar Award: For individuals who are working parents or single parents.

To apply, students must complete an online application, provide letters of reference, and write an essay detailing how their diagnosed GI condition has impacted their life and the significance of healthcare providers in managing their condition.

Application Process

The application window for the Salix Gastrointestinal Health Scholars Program will remain open until May 6, 2026. Recipients will be notified over the summer of 2026. Interested applicants can find more information, including eligibility criteria and terms and conditions, on the Salix website.

About Bausch Health

Bausch Health Companies Inc., traded on both NYSE and TSX under the ticker BHC, is a global leader in the pharmaceutical industry, with a focus on enhancing lives through improved healthcare outcomes. With a diverse portfolio, Bausch Health develops, manufactures, and markets an array of products across various therapeutic areas, including gastroenterology, hepatology, and more. Salix Pharmaceuticals, a part of this portfolio, specializes in innovative treatments for gastrointestinal diseases. For further details about their products and mission, visit Bausch Health and Salix.

Conclusion

The 2026 Salix Gastrointestinal Health Scholars Program not only highlights Bausch Health’s commitment to educational support for students facing medical challenges but also emphasizes the importance of resilience in the journey toward academic and personal achievement. By providing significant financial resources, Bausch Health aims to empower the next generation of leaders in the healthcare sector and beyond.